Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Prolonged (>24 Week) Dosing with the Oral CAM-E Compound ALG-000184 Results In Multi-log Reductions In Hepatitis B Surface Antigen, HBV DNA, And HBV RNA Levels In Untreated E Antigen Postive Subjects With Chronic Hepatitis B

Sunday, December 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study reports that prolonged dosing of the oral CAM-E compound ALG-000184 leads to significant reductions in hepatitis B surface antigen, HBV DNA, and HBV RNA levels in untreated E antigen positive subjects with chronic hepatitis B. These findings suggest the compound's potential effectiveness in managing chronic HBV infection.
Price reaction · baseline $17.5275 (2023-12-01 close) · 8 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Prolonged dosing shows significant reduction in HBV markers.
  • Results indicate potential effectiveness of ALG-000184.
  • Study targets untreated E antigen positive subjects.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is an oral CAM-E compound being studied for chronic hepatitis B treatment.

What were the results of the study?

The study found significant reductions in hepatitis B surface antigen, HBV DNA, and HBV RNA levels.

Who were the subjects in the study?

The study involved untreated E antigen positive subjects with chronic hepatitis B.

What is the significance of prolonged dosing?

Prolonged dosing may enhance the effectiveness of ALG-000184 in managing chronic HBV infection.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 hepatitis B chronic HBV HBV DNA HBV RNA
Last updated: Dec 3, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →